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Besides interferon, five oral nucleos(t)ide analogues are
currently approved for the treatment of chronic hepatitis
B (CHB): lamivudine (LAM), adefovir dipivoxil (ADV), ente-
cavir (ETV), tenofovir (TDF) and telbivudine (LdT). Treat-
ment of CHB with any single nucleoside reverse transcriptase
inhibitor (NRTI) generally leads to rapid suppression of viral
replication in the short term; however, long-term therapy
can cause the emergence of drug-resistant mutants.1,2 Lami-
vudine, the first NRTI approved for CHB therapy, is still
commonly used as the first-choice therapy for its potency,
relatively low cost and safety profile. Mutations conferring
resistance to LAM have been mapped to the C domain of the
viral reverse transcriptase (RT)3 and are often associated
with compensatory mutations in the conserved B domain that
partially restore the capacity of mutants in vitro.4,5 When
drug resistance occurs during LAM therapy, the most appro-
priate management is the early combination of LAM with
ADV6 or possibly TDF. ADV usually does not exhibit cross
resistance with LAM and undetectable viremia is obtained
after three months in 100% of patients who started combined
therapy with viremia of <6log cp/ml.7 Also, ETV is effective
in patients with LAM resistance. However, its efficacy is lower
than in naı¨ve patients and it needs to be administered in high
dose. Also, the likelihood of resistance is higher than that
observed in naı¨ve patients, because two of the three muta-
tions conferring resistance to ETVare usually present in LAM-
resistant hepatitis B virus (HBV).8
Here, we report the case of a 47-year-old male with CHB,
HBeAg-negative and anti-HBe-positive, and negative for HCV
(hepatitis C virus), HDV (hepatitis D virus) and HIV. He pre-
sented with advanced liver disease (Ishak grading 10 and
staging 5), elevated HBV DNA (528 000 UI/ml) and increased
ALT. He refused PEG-interferon and, according to the
national guidelines at that time, started therapy with LAM
in February 2006, without performing genotyping. After
three months, HBV DNA was below 200 UI/ml and ALT was
normal. HBV DNA and ALT measurements, performed every
three months, were normal until November 2007, when,
despite high adherence to the therapy regime, HBV DNA
was 412 UI/ml with a normal ALT value. After a further
month, HBV DNA had increased to 1028 UI/ml. HBV genotyp-
ing by in-house nested PCR was performed, obtaining the
following results: four primary RT mutations, L180M, A181V,1201-9712/$36.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.08.005M204V, Q215S, and several other secondary mutations,
R114H, F122L, N124H, Q130P, Q149K, F221Y, S246H, I253V,
W257Y, T259S, D263E, W287C, A317S, S332C, M336I. For HBV
sequencing, HBV DNA was extracted using a commercially
available kit (QIAmp DNA bloodmini-kit, QIagen Inc, USA) and
then amplified with Amplitaq-Gold polymerase enzyme using
primer pairs that amplify the A to E domains of RT. The
sequences were obtained by an ABI-3100 automated sequen-
cer and analyzed using SeqScape-v.2.0 software. Thesemuta-
tions not only confer resistance to LAM and LdT, but also
greatly reduce sensitivity to ADVand ETV, leaving only TDF as
a potentially suitable therapy.
This case confirms that, as recently recommended by the
American Association for the Study of Liver Diseases
(AASLD),9 when possible LAM, despite its high viral potency,
should not be used as first-line therapy for CHB, because it
can increase the likelihood of resistance to other NRTIs.
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